LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Test Differentiates Lyme Disease from Similar Condition

By LabMedica International staff writers
Posted on 29 Aug 2017
Print article
Image: A Lone star tick (Amblyomma americanum) that can be carriers of southern tick-associated rash illness (Photo courtesy of Centers for Disease Control and Prevention).
Image: A Lone star tick (Amblyomma americanum) that can be carriers of southern tick-associated rash illness (Photo courtesy of Centers for Disease Control and Prevention).
Lyme disease is the most commonly reported vector-borne illness in the USA, and current laboratory tests are not sensitive enough to detect infection with high accuracy in the first few weeks of illness. In 2015, 95% of confirmed Lyme disease cases were reported from 14 US states.

Southern Tick-Associated Rash Illness (STARI) which is characterized by a rash indistinguishable from that of Lyme disease and by possible fatigue, fever, headache, and muscle pains. The current laboratory test used for Lyme disease also cannot diagnose STARI, for which the cause is unknown.

Lyme disease is transmitted when blacklegged ticks infected with the bacterium Borrelia burgdorferi bite people, while Lone star ticks, which cause STARI, do not transmit B. burgdorferi. Scientists at Colorado State University (Fort Collins, CO; USA) and their colleagues applied an unbiased metabolomics approach with sera retrospectively obtained from well-characterized patients; they defined biochemical and diagnostic differences between early Lyme disease and STARI.

The investigators used mass spectrometry to identify biomarkers of metabolic differences in the two diseases. Specifically, the team found a metabolic biosignature consisting of 261 molecular features (MFs) that revealed altered N-acyl ethanolamine and primary fatty acid amide metabolism discriminated early Lyme disease from STARI. Development of classification models with the 261-MF biosignature and testing against validation samples differentiated early Lyme disease from STARI with an accuracy of 85% to 98%.

John T. Belisle, PhD, a professor and lead investigator of the study, said, “We were able to tell the difference between early Lyme disease and Southern Tick-Associated Rash Illness by using biomarkers that show us how the body reacts to these illnesses. This could be important in helping to more accurately detect early Lyme disease, which is crucial because the longer people wait for Lyme disease treatment, the higher the potential risk for having more severe symptoms.” The study was published on August 16, 2017, in the journal Science Translational Medicine.

Related Links:
Colorado State University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more